Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
Trial Parameters
Brief Summary
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.
Eligibility Criteria
Inclusion Criteria: * Men, Women, and all genders * Individuals 18 years old or older are included. * Patients of the study investigators and team members * Diagnosis of pancreatic ductal adenocarcinoma * All subjects must consent to this study * Clinically diagnosed weight loss Exclusion Criteria: * Minors * Pregnant Women * Any records flagged "break the glass" or "research opt out." * Patients who have received treatment for SIBO in the past 3 months